



- For release June 18, 2024 -

## Actor William Shatner Joins Oversight Committee for 130-Year Lifespan Trials


Pleasanton, CA, June 18, 2024 - Last month, Biotech Explorers and its parent company, Mitrix Bio Inc., announced the world's first trial of a bioreactor-grown mitochondrial treatment aimed at extending human lifespans to 130 years, starting with astronauts.

Now, world-renowned actor, futurist, and astronaut William Shatner has joined the project's Oversight Committee alongside other distinguished members including Dr. Michael Snyder, head of the Genetics Department at Stanford University and Dr. Thomas Rando, director of the Broad Stem Cell Research Center at UCLA.

This groundbreaking project involves a group of volunteers over 60 years old, including prominent physicians, scientists, and entrepreneurs. They will test bioreactor-grown mitochondrial transplants to potentially regenerate the body, extend healthy lifespans, and address a range of diseases such as children's mitochondrial diseases, Alzheimer's, Parkinson's, ALS, infectious diseases like COVID-19, and rapid healing of injuries. The Oversight Committee will monitor the project's progress and evaluate its success.

Mr. Shatner stated, "I have always been a futurist. The cutting edge of science is where the excitement lies, and this project is certainly at that edge."

Tom Benson, CEO of Mitrix, added, "When we announced this project for astronauts, we realized Mr. Shatner, who went into space with Blue Origin at 90 years old as the oldest astronaut, was a perfect fit. We're thrilled to have him involved."



About Biotech Explorers, a subsidiary of Mitrix Bio, Inc.

Biotech Explorers (<u>www.explorers.bio</u>), a wholly owned subsidiary of Mitrix Bio Inc. (<u>www.mitrix.bio</u>), is a Silicon Valley-based startup specializing in research on mitochondrial bioreactors. Mitrix Bio is generously funded by R42 Group, Methuselah Fund, Longevitytech.fund, and Lauder Partners, with research partnerships from Stanford University and the University of Connecticut TIP Program. Advisors include Dr. Mike Snyder, head of the

Genetics Department at Stanford, and Dr. Thomas Rando, a globally recognized authority on aging from UCLA's Broad Stem Cell Clinic. Mitrix Bio has contributed extensively to peer-reviewed research in this field.

## **Disclaimer**

The treatments discussed in this document are purely experimental, unproven, not yet tested in human patients, and not yet available for human use.

## Contact:

Biotech Explorers web site: www.explorers.bio

Mitrix Bio Inc.: www.mitrix.bio